Suven Pharmaceuticals Reports Strong Financial Performance Amid Liquidity Challenges in December 2024

Suven Pharmaceuticals has recently reported its financial results for the quarter ending December 2024, showcasing a notable performance in various key metrics. The company's score has undergone an adjustment in evaluation, reflecting a shift from -5 to 11 over the past three months.
The financial highlights indicate that Suven Pharma achieved its highest operating profit (PBDIT) at Rs 117.70 crore, marking consistent growth over the last five quarters. Similarly, profit before tax (PBT) reached Rs 94.02 crore, also the highest in this period, with a significant growth rate of 47.3% compared to the average PBT of the previous four quarters. Profit after tax (PAT) stood at Rs 82.88 crore, further emphasizing the company's upward trajectory.

On the sales front, net sales hit Rs 307.15 crore, reflecting a growth of 27.8% over the average of the previous four quarters. Earnings per share (EPS) also reached a peak of Rs 3.26, indicating enhanced profitability for shareholders.

However, the financial results also reveal some challenges. The debtors turnover ratio has declined to 5.23 times, indicating a slower pace in settling debts. Additionally, cash and cash equivalents have decreased to Rs 42.15 crore, suggesting a decline in short-term liquidity.

For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.